Leaps and bounds.

Immune checkpoint inhibitors have changed outcomes across several cancers but perhaps none more than metastatic melanoma. This NCDB analysis of patients treated for stage IV melanoma between 2016-2019 reports median overall survival times of 44 months after ICI versus a paltry 16 months after other targeted therapies or cytotoxic chemo. | Lamba, JAMA Netw Open 2022